Top 20 Contract Research Organizations 2025

This report forms part of the Ranking News Healthcare Ranking series, which evaluates hospitals, medical institutions, pharmaceutical organizations, medical technology companies, diagnostics providers, laboratories, precision medicine platforms, and healthcare systems across global healthcare markets.

Contract Research Organizations occupy a central position in the global life sciences ecosystem by supporting pharmaceutical, biotechnology, medical device, diagnostics, and advanced therapy companies throughout the drug and product development process. Their services include clinical trial design, site activation, patient recruitment, clinical monitoring, data management, biostatistics, medical writing, regulatory affairs, pharmacovigilance, real-world evidence, central laboratory services, and post-marketing research.

Unlike pharmaceutical sponsors that own therapeutic assets, CROs provide the operational, scientific, regulatory, and data infrastructure required to execute development programs efficiently across multiple countries, therapeutic areas, and trial phases. Their institutional relevance is determined not only by revenue scale, but also by clinical execution quality, therapeutic expertise, investigator networks, technology platforms, regulatory capability, and ability to manage increasingly complex studies.

The CRO sector has become more important as drug development grows more specialized. Oncology, immunology, rare disease, cell and gene therapy, neuroscience, obesity, cardiovascular disease, infectious disease, and precision medicine trials often require sophisticated protocol design, biomarker integration, decentralized trial tools, specialty site networks, and complex data systems. Sponsors increasingly rely on CROs to manage this complexity while controlling development timelines and costs.

This ranking identifies Contract Research Organizations whose platforms demonstrate sustained relevance across global clinical trial execution, therapeutic expertise, regulatory support, laboratory integration, data infrastructure, and long-term sponsor relationships. Rather than focusing only on one-year revenue, the objective is to recognize organizations whose CRO platforms remain structurally important within global healthcare and life sciences development.

Market Overview

The CRO market remains one of the most important outsourced service segments in life sciences. Pharmaceutical and biotechnology companies rely on CROs to execute clinical trials across multiple phases, geographies, therapeutic areas, and regulatory environments. The market ecosystem includes full-service global CROs, specialty clinical development providers, laboratory-linked CRO platforms, preclinical research organizations, technology-enabled trial providers, and regionally focused CROs.

The largest global CROs remain deeply embedded in drug development infrastructure. IQVIA reported full-year 2025 revenue of $16.31 billion, with R&D Solutions revenue of $8.90 billion and contracted R&D backlog of $32.7 billion, illustrating the scale of its clinical research platform. Thermo Fisher Scientific, through PPD, remains another leading platform, and its announced acquisition of Clario for up to $9.4 billion highlights the increasing importance of clinical trial software, endpoint data, and digital trial infrastructure in the CRO sector.

The competitive landscape is led by large global players such as IQVIA, ICON, Thermo Fisher / PPD, Syneos Health, Parexel, Fortrea, Medpace, Charles River Laboratories, WuXi AppTec, and Pharmaron. Industry market sources identify CRO services as an ecosystem that includes companies such as IQVIA, ICON, and Syneos Health, serving pharmaceutical, biotechnology, and medical device sponsors.

The sector is also undergoing strategic change. Advances in AI, the rise of Asia-Pacific as a global trial hub, new regulatory expectations, and scientific complexity are reshaping how clinical trials are designed and executed. Industry commentary entering 2025 identified IQVIA, ICON, Thermo Fisher / PPD, and Medpace among major CROs benefiting from stabilizing biotech funding and increased outsourcing demand.

At the same time, the industry faces pressure from sponsor budget discipline, biotech funding volatility, margin pressure, trial cancellations, site-capacity constraints, and growing expectations for technology-enabled execution. ICON’s recent accounting-related uncertainty and internal revenue investigation also illustrates that even large CROs face governance, reporting, and operational scrutiny in a complex outsourcing environment.

Industry Trend — 2025

The CRO industry in 2025 is shaped by five major trends: clinical trial complexity, digital trial infrastructure, therapeutic specialization, regional diversification, and sponsor demand for integrated outsourcing.

First, clinical trial complexity continues to increase. Modern studies frequently include biomarkers, adaptive designs, decentralized components, complex eligibility criteria, rare disease populations, real-world evidence, imaging endpoints, and companion diagnostics. CROs with strong scientific, medical, and operational expertise are better positioned to manage this complexity.

Second, digital infrastructure is becoming central. Electronic clinical outcome assessments, remote monitoring, patient engagement platforms, clinical data integration, AI-assisted site selection, risk-based monitoring, and endpoint management are now strategic capabilities rather than optional tools. Thermo Fisher’s planned acquisition of Clario reflects this broader movement toward combining CRO services with specialized clinical trial software and endpoint data platforms.

Third, therapeutic specialization is increasingly important. Oncology, rare disease, cell and gene therapy, immunology, metabolic disease, and neuroscience trials require specialized site networks, investigator relationships, patient recruitment strategies, protocol design expertise, and regulatory familiarity. CROs that can combine global scale with deep therapeutic knowledge are more defensible than generic service providers.

Fourth, Asia-Pacific continues to gain importance as a clinical development region. China, India, Japan, South Korea, Singapore, and Australia have become increasingly relevant for patient recruitment, biotech development, regulatory strategy, and global trial execution. CROs with strong APAC infrastructure are better positioned as sponsors seek broader geographic trial footprints.

Fifth, sponsor outsourcing strategies are becoming more selective. Large pharmaceutical companies increasingly prefer strategic partnerships with global CROs, while small and mid-sized biotechnology firms often seek flexible providers capable of integrated regulatory, clinical, data, and laboratory support. This creates room for both large global CROs and focused specialist CROs with strong execution records.

Methodology — Core Eligibility Criteria

To ensure structural consistency within the category, organizations considered for this ranking were evaluated based on the following eligibility conditions:

• Operates primarily as a Contract Research Organization, clinical development services provider, preclinical research services provider, or integrated life sciences development partner
• Provides services such as clinical trial management, monitoring, regulatory affairs, data management, biostatistics, pharmacovigilance, medical writing, real-world evidence, laboratory services, preclinical testing, or clinical trial technology
• Serves pharmaceutical, biotechnology, medical device, diagnostics, or advanced therapy sponsors across drug development, product development, regulatory approval, or post-marketing research
• Demonstrates meaningful scale through global or regional operations, sponsor relationships, therapeutic expertise, clinical trial infrastructure, laboratory capability, or technology platforms
• Maintains systems for quality assurance, regulatory compliance, data integrity, clinical governance, study oversight, and ethical research execution

Pure management consulting firms, software-only vendors without meaningful clinical development service capability, academic research sites, single-site trial units, and laboratory companies without meaningful research service activity were generally excluded.

Methodology — Ranking Factors

Organizations included in the ranking were evaluated using a combination of qualitative and structural considerations rather than short-term revenue alone. Key factors considered include:

• Scale and geographic reach of CRO operations
• Breadth of clinical development, regulatory, laboratory, and data services
• Therapeutic expertise in oncology, rare disease, immunology, neuroscience, metabolic disease, infectious disease, and advanced therapies
• Ability to support Phase I–IV trials, real-world evidence, and post-marketing programs
• Technology infrastructure, data systems, AI adoption, and digital trial capability
• Sponsor relationships, backlog quality, execution reliability, and quality systems
• Regulatory expertise, site network depth, patient recruitment capability, and operational resilience
• Institutional stability, brand reputation, and long-term platform relevance

The objective of the ranking is to identify CROs whose platforms maintain sustained relevance within the global healthcare and life sciences ecosystem.

The Healthcare Ranking Top 20 Contract Research Organizations 2025 ranking evaluates CROs and clinical development service providers based on operational scale, scientific expertise, sponsor relevance, global reach, technology capability, and long-term institutional resilience.

The ranking universe consisted of approximately 120 Contract Research Organizations and clinical development service providers, from which 20 organizations were selected for inclusion.

Tier classifications reflect relative institutional positioning within the CRO sector and do not represent sponsor procurement advice, investment recommendations, or regulatory endorsements.

---

Tier I — Leading Global Contract Research Organizations

IQVIA

• Headquarters: Durham, United States
• Founded: 2016
• Core focus: Clinical development, real-world evidence, healthcare data, analytics, technology-enabled research

IQVIA is one of the most important Contract Research Organizations globally, combining large-scale clinical development services with healthcare data, analytics, real-world evidence, consulting, and technology platforms. Its position is distinctive because it operates not only as a CRO, but also as a healthcare information and analytics company serving pharmaceutical, biotechnology, payer, provider, and government clients.

IQVIA’s strength lies in the integration of clinical trial operations with data infrastructure. The company can support trial design, site selection, patient identification, real-world evidence, regulatory strategy, commercial analytics, and post-marketing research through a broad platform. This makes it especially relevant for sponsors seeking evidence generation across the full product lifecycle.

The company’s 2025 performance illustrates its scale. IQVIA reported full-year 2025 revenue of $16.31 billion, R&D Solutions revenue of $8.90 billion, and R&D Solutions contracted backlog of $32.7 billion, with full-year 2025 revenue guidance of $17.15 billion to $17.35 billion.

IQVIA’s global reach, data assets, clinical development platform, analytics capability, and strategic sponsor relationships support its position as a Tier I CRO in 2025.

Thermo Fisher Scientific / PPD

• Headquarters: Waltham, United States
• Founded: 1956 / PPD founded 1985
• Core focus: Clinical development, central laboratories, bioanalytical services, trial technology, life sciences infrastructure

Thermo Fisher Scientific, through PPD and related clinical research services, is one of the largest and most strategically important CRO platforms globally. Its strength lies in the combination of clinical trial execution, laboratory services, life sciences tools, manufacturing support, and scientific infrastructure.

PPD provides full-service clinical development capabilities across therapeutic areas and trial phases, while Thermo Fisher’s broader platform adds central laboratory services, bioanalytical testing, supply-chain support, clinical trial materials, analytical technologies, and life sciences infrastructure. This makes the company unusually well positioned across both clinical operations and the supporting scientific ecosystem.

Thermo Fisher’s move to acquire Clario for up to $9.4 billion further reinforces its strategy of expanding into clinical trial software, endpoint data, and digital trial infrastructure. Clario’s platform has been used in 26,000 trials and contributed to 70% of U.S. drug approvals, according to the Financial Times report on the transaction.

Thermo Fisher / PPD’s global scale, laboratory integration, life sciences breadth, digital trial expansion, and sponsor relevance support its position as a leading global CRO.

ICON plc

• Headquarters: Dublin, Ireland
• Founded: 1990
• Core focus: Full-service clinical development, decentralized trials, data services, regulatory support

ICON plc is one of the world’s largest full-service CROs, with major capabilities across clinical trial management, site and patient services, data management, biostatistics, pharmacovigilance, regulatory affairs, decentralized trial support, and real-world evidence. Its acquisition of PRA Health Sciences significantly expanded its global scale and therapeutic coverage.

ICON’s strength lies in its ability to support large multinational clinical trials for pharmaceutical, biotechnology, and medical device sponsors. The company has deep experience across therapeutic areas including oncology, cardiovascular disease, infectious disease, neuroscience, rare disease, and vaccines.

The company remains a structurally important CRO despite recent scrutiny around accounting practices and possible revenue overstatements from 2023 to 2025. Reports noted that ICON initiated an internal investigation and withdrew guidance, while the estimated overstatement was described as less than 2% of revenue. This issue creates reputational and governance uncertainty, but it does not remove ICON’s underlying importance in the global CRO market.

ICON’s global clinical operations, large sponsor base, trial execution infrastructure, and therapeutic breadth support its Tier I position, while governance and reporting issues should remain a point of monitoring.

Parexel

• Headquarters: Durham, United States / Newton, United States
• Founded: 1982
• Core focus: Clinical research, regulatory consulting, real-world evidence, patient-focused development

Parexel is one of the most established global CROs, with long-standing capabilities across clinical trial management, regulatory affairs, biostatistics, medical writing, pharmacovigilance, market access, real-world evidence, and patient-centered development. The company has served pharmaceutical and biotechnology sponsors for decades and remains one of the most recognized names in outsourced clinical development.

Parexel’s strength lies in regulatory and clinical development experience. It is particularly relevant for sponsors seeking integrated support from protocol design and regulatory strategy through trial execution, submission support, and post-approval evidence generation.

The company has also emphasized patient-focused trial design and decentralized trial capabilities, reflecting broader industry demand for more accessible, efficient, and representative clinical research. Parexel’s experience across therapeutic areas and global regulatory environments gives it a durable institutional position.

Its long operating history, regulatory consulting strength, global clinical development platform, and sponsor relationships support its position among leading global CROs.

Medpace

• Headquarters: Cincinnati, United States
• Founded: 1992
• Core focus: Full-service clinical development, biotech-focused trials, medical and scientific oversight

Medpace is one of the strongest full-service CROs serving biotechnology and pharmaceutical sponsors, with particular strength among small and mid-sized biotech companies. The company is known for its medically led operating model, therapeutic specialization, integrated laboratory and core lab services, and disciplined execution.

Medpace’s strength lies in its focused full-service model. Many biotechnology sponsors require a CRO that can provide clinical operations, medical monitoring, regulatory support, data management, laboratory services, and scientific guidance without excessive fragmentation. Medpace is positioned to serve this segment by integrating clinical and scientific functions under one operating platform.

The company is especially relevant in oncology, metabolic disease, cardiology, central nervous system disorders, infectious disease, and rare disease trials. Its central lab, imaging core lab, and cardiac safety services add depth beyond conventional clinical monitoring.

Medpace’s biotech relevance, medical oversight model, integrated services, and strong execution reputation support its position as a Tier I CRO in 2025.

---

Tier II — Established Contract Research Organizations

(Alphabetical order)

Advanced Clinical

• Headquarters: Deerfield, United States
• Founded: 1994
• Core focus: Clinical development, functional service provider models, staffing, biometrics

Advanced Clinical is a clinical development services provider supporting pharmaceutical, biotechnology, and medical device sponsors through CRO services, functional service provider models, clinical staffing, biometrics, and trial execution support.

The company’s relevance lies in its flexible service model. Not all sponsors require full-service outsourcing; many need targeted support in clinical operations, data management, biostatistics, medical writing, or study team staffing. Advanced Clinical serves this segment by combining CRO capability with workforce and functional support.

Its model is particularly relevant for sponsors seeking scalable clinical operations without committing to the largest global CRO platforms. Advanced Clinical’s operational flexibility, sponsor support services, and clinical development expertise support its position among established CROs.

Charles River Laboratories

• Headquarters: Wilmington, United States
• Founded: 1947
• Core focus: Preclinical research, safety assessment, discovery services, biologics testing

Charles River Laboratories is one of the most important research service providers in preclinical and early-stage drug development. While it is not a conventional full-service late-stage clinical CRO, its role in discovery, toxicology, safety assessment, research models, biologics testing, and regulated preclinical studies makes it essential to the broader CRO ecosystem.

The company supports pharmaceutical, biotechnology, academic, and government clients before and alongside human clinical development. Its services help sponsors evaluate safety, pharmacology, biological activity, product quality, and translational risk.

Charles River is especially relevant as drug development becomes more biologically complex. Cell and gene therapies, biologics, RNA medicines, oncology platforms, and rare disease programs require specialized preclinical models and safety testing.

Its scientific breadth, regulated laboratory infrastructure, preclinical expertise, and long-standing sponsor relationships support its inclusion among established CROs.

Ergomed

• Headquarters: Guildford, United Kingdom
• Founded: 1997
• Core focus: Clinical development, pharmacovigilance, rare disease, oncology

Ergomed is a specialist CRO and pharmacovigilance services provider with a strong focus on rare disease, oncology, and complex clinical development programs. The company supports pharmaceutical and biotechnology sponsors through clinical trial management, regulatory support, safety services, and post-marketing pharmacovigilance.

Ergomed’s strength lies in serving complex and specialized development programs rather than competing only on global scale. Rare disease and oncology trials often require careful site selection, patient identification, regulatory coordination, and specialist investigator relationships.

The company’s pharmacovigilance capability also gives it relevance beyond trial execution. As regulatory expectations around drug safety increase, sponsors require reliable safety monitoring and post-approval risk management partners.

Ergomed’s specialist therapeutic focus, clinical development services, and pharmacovigilance infrastructure support its inclusion among established CROs.

Fortrea

• Headquarters: Durham, United States
• Founded: 2023
• Core focus: Clinical development, central labs legacy, Phase I–IV trials, regulatory services

Fortrea is a major global CRO formed from the clinical development and patient access businesses formerly associated with Labcorp. The company provides clinical trial management, pharmacovigilance, regulatory affairs, data management, clinical pharmacology, and related development services for pharmaceutical and biotechnology sponsors.

Fortrea’s strength lies in its heritage. Although recently established as an independent company, its operating capabilities derive from a long history within a major laboratory and drug development services organization. This gives it immediate relevance in global clinical development.

The company’s challenge is to establish a clear independent identity, improve execution consistency, and compete against larger integrated platforms such as IQVIA, ICON, PPD, Parexel, and Syneos. Its scale, client relationships, and global clinical infrastructure support its inclusion among established CROs.

Pharmaron

• Headquarters: Beijing, China
• Founded: 2004
• Core focus: Discovery services, preclinical research, clinical development, CMC, integrated R&D services

Pharmaron is a major China-based contract research and development organization with a broad platform spanning discovery, preclinical research, clinical development, manufacturing-related services, and laboratory support. It represents one of the most important Asia-origin CRO and CRDMO platforms.

Pharmaron’s strength lies in integrated drug R&D services. Sponsors increasingly seek partners that can support multiple stages of development, from discovery chemistry and biology through preclinical testing, clinical development, and manufacturing process support.

The company’s China base gives it relevance in one of the world’s most important and fastest-evolving biopharmaceutical markets. Its global expansion also supports sponsors seeking cost-effective, scientifically capable, and internationally connected development partners.

Pharmaron’s integrated service platform, China market relevance, discovery and preclinical depth, and expanding global footprint support its position among established CROs.

PSI CRO

• Headquarters: Zug, Switzerland
• Founded: 1995
• Core focus: Full-service clinical development, oncology, hematology, rare disease, infectious disease

PSI CRO is a privately held full-service CRO with a strong reputation in clinical trial execution, particularly for sponsors seeking operational focus, therapeutic expertise, and global study management. The company supports Phase II–III and related clinical development programs across multiple therapeutic areas.

PSI’s strength lies in its focused operating model and reputation for execution. Unlike the largest CROs, PSI is not primarily defined by massive scale or analytics platforms; instead, it emphasizes clinical trial delivery, site relationships, and sponsor service quality.

The company is especially relevant in oncology, hematology, infectious disease, rare disease, and other specialist areas where recruitment, site activation, and operational discipline are critical.

PSI CRO’s private ownership, therapeutic focus, execution reputation, and global clinical operations support its inclusion among established CROs.

Syneos Health

• Headquarters: Morrisville, United States
• Founded: 2017
• Core focus: Clinical development, commercial services, consulting, integrated biopharma solutions

Syneos Health is one of the major global CROs, combining clinical development services with commercial, consulting, and medical affairs capabilities. Its model is built around supporting sponsors from development through commercialization, making it relevant across the full product lifecycle.

Syneos’ strength lies in its integrated clinical-commercial model. Pharmaceutical companies increasingly need evidence generation, patient access planning, medical engagement, and commercialization strategy to be aligned earlier in development. Syneos is positioned to provide these linked services.

The company’s clinical development platform includes trial management, monitoring, biometrics, regulatory services, and therapeutic expertise across major disease areas. Its commercial services differentiate it from CROs focused only on trial execution.

Syneos Health’s global scale, integrated model, therapeutic breadth, and sponsor relationships support its position among established CROs.

WuXi AppTec

• Headquarters: Shanghai, China
• Founded: 2000
• Core focus: Discovery services, preclinical development, clinical research, testing, integrated R&D services

WuXi AppTec is one of the most important contract research and development platforms globally, with broad services across discovery chemistry, biology, preclinical testing, clinical research, laboratory testing, and enabling technologies for pharmaceutical and biotechnology clients.

WuXi’s strength lies in its integrated R&D service platform and China-linked scientific infrastructure. It has become a major partner for global biopharmaceutical companies seeking scale, technical capability, and integrated service coverage from early discovery through development.

The company has faced geopolitical scrutiny and regulatory risk, particularly in relation to U.S.-China life sciences policy. Nevertheless, its scientific capacity, global client base, and role in drug discovery and preclinical development remain significant.

WuXi AppTec’s integrated service capabilities, China-origin scale, discovery strength, and broad sponsor relevance support its inclusion among established CROs.

Worldwide Clinical Trials

• Headquarters: Research Triangle Park, United States
• Founded: 1986
• Core focus: Full-service clinical development, neuroscience, oncology, rare disease, cardiovascular

Worldwide Clinical Trials is a mid-sized global CRO focused on full-service clinical development across therapeutic areas including neuroscience, oncology, rare disease, cardiovascular disease, and metabolic disorders. It serves pharmaceutical and biotechnology sponsors seeking a more specialized alternative to the largest CRO platforms.

The company’s strength lies in therapeutic focus and operational flexibility. Mid-sized sponsors often prefer CROs that can provide senior attention, medical expertise, and tailored execution rather than a highly standardized large-provider model.

Worldwide is especially relevant in neuroscience and rare disease, where trial design, patient recruitment, site selection, and outcome assessment can be particularly challenging. Its focused clinical development model supports its position among established CROs.

WCG Clinical

• Headquarters: Princeton, United States
• Founded: 1968 / WCG platform evolved later
• Core focus: IRB review, clinical trial services, site support, study start-up, ethical oversight

WCG Clinical occupies a specialized but important position within the CRO ecosystem. It is best known for institutional review board services, ethical review, study start-up support, clinical trial technology, endpoint services, and site-related trial infrastructure.

WCG’s relevance lies in trial governance and site enablement. Clinical trials require ethical review, participant protection, regulatory compliance, study activation, and site support before operational execution can begin. These services are essential even if they are not always visible in sponsor-facing CRO rankings.

The company’s platform supports sponsors, CROs, academic sites, and investigators by reducing friction in study activation and regulatory oversight. WCG’s specialized role in clinical trial infrastructure supports its inclusion among established CRO service platforms.

---

Tier III — Specialist Contract Research Organizations

(Alphabetical order)

Avance Clinical

• Headquarters: Adelaide, Australia
• Founded: 2019
• Core focus: Early-phase clinical trials, biotech-focused development, Australia and Asia-Pacific trials

Avance Clinical is an Australian CRO focused on supporting biotechnology companies through early-phase and later-stage clinical development programs. The company is especially relevant for sponsors seeking to use Australia’s clinical trial environment, regulatory pathways, and investigator networks.

Its strength lies in biotech-focused execution and regional specialization. Australia has become an attractive destination for early clinical development due to relatively efficient trial start-up, strong clinical infrastructure, and government incentives for eligible R&D activity.

Avance Clinical’s focus on biotechnology sponsors, Asia-Pacific execution, and clinical development support makes it a suitable Tier III specialist CRO.

Celerion

• Headquarters: Lincoln, United States
• Founded: 2010
• Core focus: Early clinical research, clinical pharmacology, bioavailability, bioequivalence

Celerion is a specialist CRO focused on early clinical research and clinical pharmacology. Its services include first-in-human studies, pharmacokinetic and pharmacodynamic evaluation, bioavailability, bioequivalence, and early development support.

The company’s relevance lies in the early stages of human drug development, where sponsors need high-quality clinical pharmacology data to guide dose selection, safety assessment, and development decisions.

Celerion’s specialization in early-phase research, clinical pharmacology, and human drug development infrastructure supports its inclusion among specialist CROs.

Clario

• Headquarters: Philadelphia, United States
• Founded: 2021
• Core focus: Clinical trial endpoint technology, eCOA, cardiac safety, imaging, respiratory endpoints

Clario is a clinical trial technology and endpoint services company supporting pharmaceutical and biotechnology sponsors through electronic clinical outcome assessments, cardiac safety, medical imaging, respiratory endpoints, and trial data solutions.

While Clario is not a traditional full-service CRO, it is a proper operating company and a significant service provider within the clinical research ecosystem. Its relevance lies in endpoint data, which is increasingly important as trials depend on reliable digital outcomes, imaging endpoints, wearable data, and specialized measurement systems.

Clario’s role in trial data generation, endpoint integrity, and digital clinical research infrastructure supports its inclusion as a specialist CRO-adjacent provider within Tier III.

LabConnect

• Headquarters: Johnson City, United States
• Founded: 2002
• Core focus: Central laboratory services, sample management, clinical trial logistics

LabConnect is a specialist provider of central laboratory services and clinical trial sample management. The company supports sponsors through laboratory network coordination, sample logistics, kit management, biospecimen tracking, and trial-specific laboratory workflows.

Its relevance lies in the operational backbone of clinical research. Many clinical trials require reliable sample collection, shipment, processing, storage, and testing across multiple sites and countries. Errors in sample management can compromise trial data integrity.

LabConnect’s specialization in clinical trial laboratory logistics and sample management makes it a meaningful specialist provider within the CRO ecosystem.

Precision for Medicine

• Headquarters: Bethesda, United States
• Founded: 2012
• Core focus: Biomarker-driven clinical development, oncology, rare disease, advanced therapies

Precision for Medicine is a specialist CRO focused on biomarker-driven clinical development, oncology, rare disease, cell and gene therapy, and advanced therapeutics. The company supports sponsors through clinical trial execution, biomarker strategy, laboratory services, regulatory support, and data-driven development planning.

Its strength lies in precision medicine-oriented research. Modern trials increasingly require biomarker selection, molecular testing, companion diagnostic coordination, biospecimen logistics, and targeted patient recruitment. Precision for Medicine is positioned around these needs.

The company’s focus on complex therapeutic areas and biomarker-enabled development supports its inclusion among specialist CROs.

---

Remarks

Contract Research Organizations continue to serve as essential infrastructure for pharmaceutical, biotechnology, medical device, diagnostics, and advanced therapy development. Their role extends beyond operational trial execution into regulatory strategy, data management, laboratory services, real-world evidence, pharmacovigilance, patient recruitment, and technology-enabled clinical development.

The organizations recognized in this ranking represent CROs and research service providers whose platforms maintain sustained relevance across clinical development, preclinical research, laboratory support, trial technology, regulatory affairs, and evidence generation. Tier classification reflects relative institutional positioning within the CRO sector rather than direct sponsor procurement guidance.

Tier classification reflects relative clinical trial scale, therapeutic expertise, regulatory capability, technology adoption, data infrastructure, sponsor relationships, execution reliability, and long-term platform resilience. The ranking does not constitute a procurement recommendation, investment recommendation, regulatory endorsement, or evaluation of individual investigators, monitors, or clinical research teams.

---

Recognition

Organizations included in the Top 20 Contract Research Organizations 2025 ranking may request information regarding authorized use of the Ranking News designation for marketing and communications purposes.

Recognized institutions may reference the designation in:

• corporate websites
• investor communications
• marketing materials
• institutional presentations
• academic and recruitment materials

Licensing inquiries:
[email protected]